ABSTRACT
Objective To evaluate the efficacy and safety of nemonoxacin as a combination drug in the treatment of patients with adult community acquired pneumonia (CAP) in the Department of Respiratory. Methods The data of patients with CAP treated with nemonoxacin as an agent in a combined therapy and admitted to Department of Respiratory of Shengjing Hospital of China Medical University from July to October 2018 were retrospectively analyzed. The patients' symptoms, curative effects and adverse reactions were recorded. Results Totally 48 patients with CAP were treated with combined nemonoxacin, including 6 patients with severe pneumonia. All the patients were treated with intravenous drip of β-lactams combined with oral nemonoxacin 500 mg, once a day. After 3 days of treatment, the improvement rate of symptoms was 47.92% (23/48), and 89.58% (43/48) of the patients were cured or improved after (9.83±3.49) days of treatment, no adverse reactions occurred during the period of oral administration;91.67% (44/48) of the patients were satisfied with the effect of medication. Compared with 178 CAP patients who were hospitalized in Department of Respiratory in the same period in 2017, the patients' length of stay in hospital in the present study was shorter (days: 12.52±4.45 vs. 14.53±6.73, P < 0.05). Conclusion As a combination drug, nemonoxacin is a safe and effective treatment for CAP patients admitted to Department of Respiratory, it can better control symptoms, shorten hospitalization time, induce less adverse reactions and its patients' tolerance is good.
ABSTRACT
OBJECTIVE: To evaluate the antibacterial activity of levofloxacin, moxifloxacin and nemonoxacin against Staphylococcus aureus in vitro. To assesse the impact of gyrA and parC genes mutant on resistance for quinolones and the sequences of gyrA and parC genes for three quinolones. METHODS: The MICs of 50 S. aureus were detected by agar dilution method. The MIC and MPC against four S. aureus which were special gene mutations were detected by agar dilution method. Based on these results, bacterial recovery growth curve of levofloxacin, moxifloxacin and nemonoxacin were traced. RESULTS: Nemonoxacin demonstrated activities 8- to 32- fold more potent(MICs at which 90% of isolates were inhibited, 0.5 μg·mL-1) than those of moxifloxacin(MIC90, 2 μg·mL-1) and levofloxacin (MIC90, 16 μg·mL-1) against 50 S. aureus.In condition of the same drug concentrations, the bacterial recovery growth ratios of nemonoxacin was the lowest, while levofloxacin's was the highest. RN450A3 recovery growth ratio was highest compared with other mutant bacterial strains, while RN450 recovery growth ratio was lowest. CONCLUSION: The antibacterial activities of nemonoxacin, moxifloxacin and levofloxacin against S. aureus in vitro are:nemonoxacin> moxifloxacin >levofloxacin. Compared with levofloxacin and moxifloxacin, nemonoxacin inhibits bacteria in a lower concentration, and nemonoxacin is utterly efficacious with different genes mutant strains.The target preference of levofloxacin may be the parC gene of topoisomerase IV, while moxifloxacin and nenomoxacin can almost act on the gyrA and parC gene at the same time.